Genapsys Stock
DNA Sequencing Technology
Sign up today and learn more about Genapsys Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Genapsys Stock
GenapSys is a sequencing technology company that aims to help support the control and limit the spread of current and future outbreaks. The company's main goal is to transform research and diagnostics with an affordable, scalable genomic sequencing ecosystem.
In July 2022, Genapsys filed for Chapter 11 bankruptcy.
GenapSys was founded in 2010 and is headquartered in Redwood City, California. Notable investors include Decheng Capital, Oxford Finance Corporation, and Farallon Capital Management.
Investors
Casdin Capital
23andMe, Komodo Health, Genapsys, ORIC Pharmaceuticals, Codiak Biosciences, Vineti
Decheng Capital
Foresite Capital
EverlyWell, Crossover Health, Aetion, Genapsys, Mindstrong, DNAnexus
Oxford Finance Corporation
Plug and Play
BigID, ApplyBoard, Caresyntax, Genapsys, Albert, Beyond Pricing
Funding History
| March 2013 | $8.5M |
|---|---|
| November 2013 | $36.5M |
| December 2017 | $86.2M |
| February 2021 | $70.6M |
Management
Chief Executive Officer
Jason Myers
Chief Financial Officer
Britton Russell
Press
law360 - Jul, 6 2023
Paul Hastings Accused Of Causing 'Demise' Of GenapSyswsj - Aug, 17 2022
GenapSys Founder Loses Fight to Have Chapter 11 Bankruptcy Dismissedmarketwatch - Aug, 5 2022
Bankrupt Genapsys Fails to Get Approval for Financing and Sale Processgenomeweb - Jul, 19 2022
Top Five Articles on GenomeWeb Last Week: Illumina, BGI, Grail, Genapsys, Morelaw360 - Jul, 14 2022
GenapSys Opens Ch. 11 After Chancery Shakes Up Boardgenomeweb - Jul, 9 2022
Sequencing Firm Genapsys, Mired in Lawsuits, Explores Bankruptcylaw360 - Jun, 13 2022
Del. Court Denies Ex-CEO GenapSys Committee Accessbiospace - Sep, 9 2021
Genapsys Adds to its Leadership Team with Two New Hiresbiospace - Aug, 5 2021
GenapSys Welcomes Ryan Walters, Ph.D. as Chief Product Officergenomeweb - Jun, 3 2021
Resolve Biosciences: Chris Barbazettedlvr - May, 27 2021
Electronic Sequencing Platform GenapSys Raises $70 Millionprnewswire - May, 27 2021
GenapSys Announces $70 Million in Series D Equity Financing and Expansion of its Board of Directorszpr - Feb, 4 2021
GenapSys Names Jason Myers CEOgenomeweb - Jan, 26 2021
Bioron to Distribute GenapSys Sequencing Technology in Germanygeekwire - Jan, 5 2021
Well-funded stealthy biotech startup Nautilus hires former Smartsheet, Isilon, GenapSys execsBusiness Wire - Dec, 23 2020
Global Next-generation Sequencing Market (2020 to 2025)nanalyze - Nov, 15 2020
GenapSys Finally Commercializes Desktop DNA SequencerEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
